4.4 Article

Evaluating the drug use gateway theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys

期刊

DRUG AND ALCOHOL DEPENDENCE
卷 108, 期 1-2, 页码 84-97

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2009.12.001

关键词

Tobacco; Alcohol; Illicit drugs; Gateway; WHO World Mental Health Surveys

资金

  1. United States National Institute of Mental Health [R01MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R01-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly & Company Foundation
  8. Ortho-McNeil Pharmaceutical, Inc.
  9. GlaxoSmithKline
  10. Bristol-Myers Squibb
  11. Ministry of Social Protection
  12. European Commission [QLG5-1999-01042, SANCO 2004123]
  13. Piedmont Region (Italy)
  14. Fondo de Investigacion Sanitaria, Institut de Salud Carlos III, Spain [FIS 00/0028]
  15. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  16. Departament de Salut, Generalitat de Catalunya, Spain, Institut de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  17. Israel National Institute for Health Policy and Health Services Research
  18. National Insurance Institute of Israel
  19. Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKOR0-013]
  20. Lebanese Ministry of Public Health, the WHO (Lebanon), Fogarty International, Act for Lebanon
  21. Janssen Cilag
  22. Eli Lilly
  23. Roche
  24. Novartis
  25. The National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  26. National Council on Science and Technology [CONACyT-G30544-H]
  27. PanAmerican Health Organization (PAHO)
  28. New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council
  29. WHO (Geneva)
  30. WHO (Nigeria)
  31. Federal Ministry of Health, Abuja, Nigeria
  32. US National Institute of Mental Health [R01-MH059575, R01-MH61905, U01-MH60220]
  33. South African Department of Health
  34. University of Michigan
  35. National Institute of Drug Abuse (NIDA)
  36. Substance Abuse and Mental Health Services Administration (SAMHSA)
  37. Robert Wood Johnson Foundation [044708]
  38. John W. Alden Trust
  39. NIDA [DA010075, DA024260, DA15454]
  40. The Patrick and Catherine Weldon Donaghue Medical Research Foundation
  41. Australian Government Department of Health and Ageing
  42. Australian National Health and Medical Research Council (NHMRC)

向作者/读者索取更多资源

Background: It is unclear whether the normative sequence of drug use initiation, beginning with tobacco and alcohol, progressing to cannabis and then other illicit drugs, is due to causal effects of specific earlier drug use promoting progression, or to influences of other variables such as drug availability and attitudes. One way to investigate this is to see whether risk of later drug use in the sequence, conditional on use of drugs earlier in the sequence, changes according to time-space variation in use prevalence. We compared patterns and order of initiation of alcohol, tobacco, cannabis, and other illicit drug use across 17 countries with a wide range of drug use prevalence. Method: Analyses used data from World Health Organization (WHO) World Mental Health (WMH) Surveys, a series of parallel community epidemiological surveys using the same instruments and field procedures carried out in 17 countries throughout the world. Results: Initiation of gateway substances (i.e. alcohol, tobacco and cannabis) was differentially associated with subsequent onset of other illicit drug use based on background prevalence of gateway substance use. Cross-country differences in substance use prevalence also corresponded to differences in the likelihood of individuals reporting a non-normative sequence of substance initiation. Conclusion: These results suggest the gateway pattern at least partially reflects unmeasured common causes rather than causal effects of specific drugs on subsequent use of others. This implies that successful efforts to prevent use of specific gateway drugs may not in themselves lead to major reductions in the use of later drugs. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据